KCR

Kezar Life Sciences Reports Second Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, August 10, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Total, KCR, European Renal Association, Autoimmune hepatitis, Week, Cohort, European Alliance of Associations for Rheumatology, Pharmacokinetics, AIH, G&A, ERA, Congress, CRR, Patient, NKF, National Kidney Foundation, ALT, KZR, EULAR, AST, Safety, European Alliance, UPCR, PANLAR, Pharmaceutical industry, Rare-earth element, Vaccine, Rheumatology, LN

Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune mediated and oncologic disorders, today reported financial results for the second quarter ended June 30, 2023 and provided a business update.

Key Points: 
  • Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune mediated and oncologic disorders, today reported financial results for the second quarter ended June 30, 2023 and provided a business update.
  • The complete MISSION Phase 1b/2 results were presented as an oral presentation at the LUPUS & KCR 2023 meeting, which took place May 17-20, 2023 in Seoul, Korea.
  • Research and development expenses for the second quarter of 2023 increased by $9.7 million to $21.0 million compared to $11.3 million in the second quarter of 2022.
  • General and administrative (G&A) expenses for the second quarter of 2023 increased by $0.8 million to $5.8 million compared to $5.0 million in the second quarter of 2022.

KCR Research Corporation Issues the Latest Analyst Report for Daiki Axis Co., Ltd. (4245, Tokyo Stock Exchange Prime).

Retrieved on: 
Wednesday, July 12, 2023
Carbon, Maintenance, Housing, KCR, Drinking water, Atmosphere, FIT, COVID-19, Sewage, Refrigeration, Research, Ministry, Nursing, Acquisition, Investment, DCM, ESCO, Water, Tokyo Stock Exchange, Groundwater, Air conditioning, Environment, Ministry of the Environment, Conservation and Parks, Transport, Energy, Demonstration, PROTECT, TSE, Renewable energy, Pharmaceutical industry

Daiki Axis Group is engaged in various businesses, including environmental equipment, household equipment, and renewable energy operations.

Key Points: 
  • Daiki Axis Group is engaged in various businesses, including environmental equipment, household equipment, and renewable energy operations.
  • Maintenance services cover facilities sold and constructed by the group, as well as maintenance of equipment from other manufacturers.
  • Dedicated departments ensure a 24-hour monitoring system and provide spot maintenance, establishing maintenance systems tailored to customer needs.
  • To further access analyst reports (KCR RESEARCH CORPORATION issued) please use the link below.

Kezar Life Sciences Reports First Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, May 11, 2023
Biotechnology, Pharmaceutical, Health, Oncology, Abstract, Total, KCR, Therapy, Autoimmune hepatitis, European Renal Association, Week, European Alliance of Associations for Rheumatology, Pharmacokinetics, AIH, G&A, ERA, Congress, CRR, Patient, NKF, Lupus nephritis, Drug discovery, National Kidney Foundation, ALT, KZR, Kezar Pavilion, EULAR, Research, AST, Safety, European Alliance, UPCR, PANLAR, Pharmaceutical industry, Rare-earth element, Rheumatology, LN

Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune mediated and oncologic disorders, today reported financial results for the first quarter ended March 31, 2023 and provided a business update.

Key Points: 
  • Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune mediated and oncologic disorders, today reported financial results for the first quarter ended March 31, 2023 and provided a business update.
  • Kezar plans to initiate the dose expansion study in the second half of 2023, with topline data expected starting mid-2024.
  • Kezar plans to report safety and dose escalation data from this trial in the second half of 2023.
  • Research and development expenses for the first quarter of 2023 increased by $7.4 million to $18.3 million compared to $10.9 million in the first quarter of 2022.

Science 37 Adds New Head of Quality, Irena Lambridis

Retrieved on: 
Tuesday, April 18, 2023
Science, KCR, GXP, Center of excellence, Computer, GCP, Science 37, RESEARCH, Patient, Quality assurance, ChromeOS, PARK, Pharmaceutical industry

RESEARCH TRIANGLE PARK, N.C., April 18, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the industry-leading Metasite™, today announced the appointment of Irena Lambridis as its Global Head of Quality Assurance & Compliance.

Key Points: 
  • RESEARCH TRIANGLE PARK, N.C., April 18, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the industry-leading Metasite™, today announced the appointment of Irena Lambridis as its Global Head of Quality Assurance & Compliance.
  • "We are thrilled to welcome Irena to our senior leadership team," said David Coman, CEO of Science 37.
  • "I am excited to join Science 37's experienced, patient-focused team and help bring new therapies to market faster," said Lambridis.
  • Her appointment reflects the company's ongoing commitment to excellence and will be key to driving greater efficiency, speed, and scale as Science 37 expands its global reach.

Kezar Life Sciences Reports Fourth Quarter and Year End 2022 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, March 14, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Society, Assistant, KZR, Annual general meeting, Autoimmune hepatitis, American College of Rheumatology, ACR, Asian literature, CRR, National Kidney Foundation, Cohort, Indiana University, Protein, Event, SITC, Patient, American College, AST, ASN, Research, UPCR, G&A, Week, Safety, Clinical trial, KCR, Total, Immunotherapy, NKF, Lupus nephritis, Pharmacokinetics, ALT, AIH, Sec61, Kezar Pavilion, Pharmaceutical industry, Vaccine, Video game, LN, Medicine

Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune mediated and oncologic disorders, today reported financial results for the fourth quarter and year ended December 31, 2022 and provided a business update.

Key Points: 
  • Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune mediated and oncologic disorders, today reported financial results for the fourth quarter and year ended December 31, 2022 and provided a business update.
  • “We made tremendous progress in both of our first-in-class programs during 2022,” said John Fowler, Kezar’s Co-founder and Chief Executive Officer.
  • Research and development expenses for the fourth quarter of 2022 increased by $5.1 million to $14.9 million compared to $9.8 million in the fourth quarter of 2021.
  • General and administrative (G&A) expenses for the fourth quarter of 2022 increased by $0.9 million to $5.2 million compared to $4.3 million in the fourth quarter of 2021.

Lunit Showcases AI Solutions for Radiology at AOCR & KCR 2022

Retrieved on: 
Wednesday, September 21, 2022
Culture of Korea, Mammography, COVID-19, AOCR, FDA, Breast cancer, CEO, Solution, KCR, Congress, Multimedia, AI, INSIGHT, Medical device, Radiology

SEOUL, South Korea, Sept. 21, 2022 /PRNewswire/ --Lunit, a leading medical AI provider, announced its participation in the 78th Annual Meeting of the Korean Society of Radiology (KCR 2022) from September 20 to 24.

Key Points: 
  • SEOUL, South Korea, Sept. 21, 2022 /PRNewswire/ --Lunit, a leading medical AI provider, announced its participation in the 78th Annual Meeting of the Korean Society of Radiology (KCR 2022) from September 20 to 24.
  • Held in conjunction with the 20th Asian Oceanian Congress of Radiology (AOCR 2022), the joint congress is expected to welcome nearly 5,000 visitors from 60 countries.
  • This year's event marks Lunit's first participation as an official major sponsor for KCR and AOCR's offline annual meeting.
  • In line with this year's KCR & AOCR 2022 theme, "Together!

SHIKIGAKU' Business Strategies and Earnings Reviewed by KCR

Retrieved on: 
Wednesday, December 8, 2021
Tokyo Stock Exchange, OECD, Advertising, Company, TSE, Research, EBITDA, Motion, Growth, ROE, Capital, Consciousness, Industry, Sports entertainment, Depreciation, Organization, Flexible Support Fund, Consultant, Logic, Time, Mother, KCR, Acquisition, Management

In this report, KCR provides analysis of the company's business model and earnings.

Key Points: 
  • In this report, KCR provides analysis of the company's business model and earnings.
  • The company's existing businesses include its core Organization Consulting business; the Sports Entertainment business, which consists mainly of a B2 League basketball team that the Companyacquired to expand its business domain; and the VC Fund business.
  • Additionally, the Company has launched a Hands-On Support Fund business and a Contract Development business as new businesses.
  • The Company is also endeavoring to prove the utility of its Shikigaku theory in all of its other business domains by developing for-profit business operations within these areas.

Daiki Axis' Business Strategies and Earnings Reviewed by KCR

Retrieved on: 
Tuesday, November 23, 2021
Government, Sale, Wind, Time, Acquisition, ASEAN, Company, Exercise, Awareness, Woman, Regional Comprehensive Economic Partnership, ESG, Risk management, COVID-19, FIT, PROTECT, Research report, RCEP, Research, Water, ESCO, Kubota, KCR, Maintenance, Groundwater, Drinking water, FRP, Certification, Growth, TSE1, Renewable energy

TOKYO, Nov. 22, 2021 /PRNewswire/ -- Daiki Axis Co., Ltd. (TOKYO:4245) , an eco-creation and development company that creates social infrastructure centered on water-related businesses, recently has been reviewed by KCR Inc., an independent research and investor relations support company providing reports on various publicly traded Japanese companies. In this report, KCR provides analysis of the company's business model and earnings.

Key Points: 
  • In this report, KCR provides analysis of the company's business model and earnings.
  • Daiki Axis Co., Ltd. (TSE1: 4245) has adopted PROTECT CHANGE ("protect the global environment" and "change the future of humanity") as a corporate mission and slogan.
  • Daiki Axis is actively expanding its business operations in the field of overseas water-related infrastructure.
  • Daiki Axis is characterized by its high efficiency benchmarks and its well-systematized turnover of capital.

KCR Opens New Branch in Sydney, Australia

Retrieved on: 
Wednesday, March 3, 2021
Health, Other Science, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, KCR CRO, Pharmaceutical industry, KCR

KCR, the international clinical development solutions provider, today announced the establishment of a new branch in Sydney, Australia.

Key Points: 
  • KCR, the international clinical development solutions provider, today announced the establishment of a new branch in Sydney, Australia.
  • KCR has further plans to open an Asian hub in South Korea once pandemic travel restrictions are lifted.
  • If you are interested in cooperating with KCR Australia or would like to learn more about our organization, please contact us at [email protected] .
  • KCR operates now across five main regions: North America, Western Europe, Central Europe, Eastern Europe and Australia, with a main operational hub located in Boston, MA.

KCR Announces New Chief Commercial Officer

Retrieved on: 
Tuesday, January 14, 2020
Biotechnology, Pharmaceutical, Health, Medical devices, KCR, San Diego State University

KCR, the international clinical development solutions provider, announced today that Bryan Katz has joined the organization in the role of Chief Commercial Officer.

Key Points: 
  • KCR, the international clinical development solutions provider, announced today that Bryan Katz has joined the organization in the role of Chief Commercial Officer.
  • Mr. Katz will oversee the expansion of KCR global commercial solutions and partnerships.
  • We are honored to have Bryan joining KCR as we continue to expand our geographical reach and develop our global partnerships.
  • We feel that Bryans experience and knowledge will be a significant contribution to making the next step in KCR commercial development, especially as we focus on the US market, summarizes KCR CEO, Mike Jagielski.